Entera Bio is a clinical-stage biotechnology company developing tablet-based peptide and protein replacement therapies for conditions with significant unmet medical needs. Its N-Tab® platform is designed to protect peptides in the gastrointestinal tract and promote their absorption into the bloodstream, with the aim of making these therapies available in convenient oral tablet form.

The company’s pipeline includes EB613, an oral PTH(1-34), or teriparatide, tablet being developed as a once-daily bone-forming treatment for postmenopausal women with osteoporosis who are at high risk of fracture. Entera is also developing EB612, an oral PTH(1-34) replacement therapy for people with hypoparathyroidism. In addition, its research programs include an oral oxyntomodulin peptide targeting GLP-1 and glucagon pathways for obesity, and an oral GLP-2 tablet for rare malabsorption conditions such as short bowel syndrome. The short bowel syndrome program is being developed in collaboration with OPKO Health. Entera Bio shares information about its technology, clinical programs, research, corporate governance, and investor updates.